AHCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AHCO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has improving revenue and supportive insider/hedge fund buying, but the technical setup is still weak and the latest quarter showed lower-than-guidance EBITDA and falling gross margin. For an impatient investor who does not want to wait for a better entry, this is still a hold rather than a buy.
Trend is mixed to weak. MACD histogram is negative and still expanding lower, which points to downward momentum. RSI_6 at 31.24 is near oversold but not a clean reversal signal. Moving averages are converging, suggesting the stock may be trying to base, but it has not confirmed a bullish breakout. Price at 11.75 is below the pivot 12.295 and only slightly above support at 11.291, so near-term upside is not confirmed. The recent pattern model suggests limited short-term edge, with roughly flat to slightly negative next-week expectations.
["Q1 2026 revenue rose 5.4% YoY to $819.8M, beating expectations.", "Canaccord, Baird, UBS, and Truist remain positive overall with Buy/Outperform-style ratings from several firms.", "Hedge funds are buying aggressively, and insiders are also buying strongly.", "The company appears positioned to gain share in DME and benefit from capitated contract demand trends."]
["Q1 adjusted EBITDA missed guidance, which triggered a pullback.", "GAAP EPS was -$0.12, missing expectations.", "Gross margin fell materially year over year to 12.37%.", "Jefferies only rates it Hold and lowered its target to $11, highlighting volume concerns.", "MACD remains bearish and price is still below key pivot resistance."]
In Q1 2026, AdaptHealth posted revenue of $819.8M, up 5.39% YoY, which is the best sign in the latest quarter. Net income improved but remained negative at -$16.0M, and EPS improved to -$0.12 but still missed expectations. The main weakness was profitability quality: gross margin dropped to 12.37%, and EBITDA came in below guidance. For a long-term buyer, revenue growth is positive, but margin compression keeps the quarter from looking fully healthy.
Analyst sentiment is moderately positive but not unanimous. UBS cut its target to $14 while keeping Buy, Canaccord raised to $16 and kept Buy, Baird raised to $18 and kept Outperform, Truist raised to $14 and stayed Buy, while Jefferies raised to $11 but kept Hold. The overall Wall Street view is cautiously bullish: pros point to share gains, secular healthcare demand, defensive characteristics, and improving capital allocation, while cons focus on volume uncertainty, weak EBITDA execution, and margin pressure. Net takeaway: analysts see upside, but confidence is tempered by operational misses.
